Dossier assessment

Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Status
Status: Commission completed
Project no.
A20-46
Last updated

Report documents

  1. Extract of dossier assessment

    Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

    published on
    Document type
    PDF document, 530 kB, EN, not accessible
  2. Dossier assessment

    Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

    published on
    Document type
    PDF document, 1 MB, DE, not accessible

Dossier assessment

Indication:

Patients with high-risk non-metastatic castration-resistant prostate cancer

Result of dossier assessment:

Disadvantages in some side effects do not question advantages particularly in overall survival; hint of considerable added benefit.

Press releases

Castration-resistant prostate cancer at high risk of metastasis: enzalutamide has added benefit

New data from the PROSPER study show advantage in overall survival

Project details

Project no.
A20-46
Commission
Commission awarded on 15.05.2020 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A18-80
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Enzalutamide (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)

    Project no.
    A14-48
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Enzalutamide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

    Project no.
    A13-33
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-77
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form